SCHEDULE: Cormorant Asset Management Discloses 12.82% Stake in Corbus Pharma

Cormorant Asset Management, LP and Bihua Chen have disclosed a 12.82% beneficial ownership stake in Corbus Pharmaceuticals Holdings, Inc., holding 2,375,000 shares.

Summary

• Cormorant Asset Management, LP and Bihua Chen collectively beneficially own 2,375,000 shares of Corbus Pharmaceuticals Holdings, Inc. Common Stock.
• This ownership represents 12.82% of the company's outstanding Common Stock.
• The percentage is calculated based on 18,528,517 shares outstanding following a public offering that was expected to close on November 3, 2025.
• The shares are held by certain funds advised by Cormorant Asset Management, LP (the "Cormorant Funds").
• Both Cormorant Asset Management, LP and Bihua Chen (as managing member) share voting and dispositive power over all 2,375,000 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The disclosure of a significant institutional stake (12.82%) by Cormorant Asset Management is generally a positive signal, indicating investor confidence. The statement that the holding is in the ordinary course of business and not for control purposes suggests a strategic investment rather than an activist one.

Positives

• A significant 12.82% stake by an institutional investor like Cormorant Asset Management may signal confidence in Corbus Pharmaceuticals' long-term prospects.
• The investment is stated to be in the ordinary course of business, indicating a standard portfolio investment rather than an activist position.

Negatives

• The filing itself does not contain explicit negative information regarding Corbus Pharmaceuticals' operations or financial health.

Risks

• The concentration of a significant portion of the company's shares (over 5%) in a single fund (Cormorant Global Healthcare Master Fund, LP) could lead to volatility if that fund decides to significantly alter its position.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Stakeholder Impact

• Shareholders: The presence of a significant institutional investor like Cormorant Asset Management can provide a degree of stability and validation for other investors.
• Company Management: A large institutional holder may exert influence through voting power, even if not seeking control, potentially impacting strategic decisions.

Key Dates

Keywords

Corbus Pharmaceuticals, Cormorant Asset Management, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals